Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'
- PMID: 25556084
- DOI: 10.1016/j.ejvs.2014.11.019
Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'
Comment in
-
Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.Eur J Vasc Endovasc Surg. 2015 Mar;49(3):353-4. doi: 10.1016/j.ejvs.2014.12.007. Epub 2014 Dec 30. Eur J Vasc Endovasc Surg. 2015. PMID: 25556083 No abstract available.
Comment on
-
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.Eur J Vasc Endovasc Surg. 2014 Nov;48(5):565-75. doi: 10.1016/j.ejvs.2014.05.001. Epub 2014 Jun 18. Eur J Vasc Endovasc Surg. 2014. PMID: 24951377
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
